Markets.com Logo

ATAI

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    3.9011$
  • Previous Close
    4.4322$
  • 52 Week Change
    3.50$
  • Day Range
    -0.53$
  • 52 Week High/Low
    1.03$ - 4.5288$
  • Dividend Per Share
    --
  • Market cap
    851 M$
  • EPS
    -0.14
  • Beta
    1.552
  • Volume
    --

About

ATAI Life Sciences N.V. (ATAI.US) is a global biopharmaceutical company focused on developing innovative mental health treatments, particularly psychedelic and non-psychedelic compounds. The company invests in and incubates a portfolio of companies working on various therapeutic approaches for conditions like depression, anxiety, and substance use disorders. ATAI is publicly traded on the Nasdaq Stock Market under the ticker symbol ATAI.

Iran War Threatens US Labor Market's 'Wonderful Balance': A Deep Dive

Emma Rose|--

Iran's Hormuz Toll Strategy: Post-War Economic Leverage and Geopolitical Realignment

Sophia Claire|--

US Labor Market Outlook: Balancing Recovery Against Escalating Geopolitical Risks

Sophia Claire|--

Global Debt Crisis Deepens Amidst Iran Conflict and Fiscal Fragility

Ava Grace|--

Apple's Strategic Pivot: MacBook Neo, Supply Chain Tactics, and Foldable Phone Hurdles

Emma Rose|--

Gold and Silver: The Greatest Bull Market Has Begun - Early Stages and Correction Analysis

Emma Rose|--

US Labor Market Navigates Dual Pressures: External Shocks and Internal Slowdown

Ava Grace|--

Factors

Company Performance: Atai Life Sciences' financial health and operational success, including revenue growth, profitability, and progress in clinical trials for its psychedelic compounds, significantly impacts investor confidence and stock price.

Regulatory Landscape: Changes in regulations concerning psychedelic drug development and potential legalization can dramatically affect investor sentiment and the perceived market opportunity for Atai, driving price fluctuations.

Clinical Trial Results: Positive data from clinical trials of Atai's therapeutic candidates boosts investor confidence and increases the stock price. Conversely, negative or inconclusive results can lead to a decline.

Market Sentiment: General market conditions, investor risk appetite, and overall sentiment towards the biotechnology and pharmaceutical sectors can influence Atai's stock price, regardless of company-specific news.

Competition: The emergence of new competitors in the psychedelic medicine space or advancements by existing rivals can impact Atai's market share and stock valuation.

Partnerships and Acquisitions: Strategic partnerships, collaborations, or acquisitions by Atai can signal growth potential and attract investors, while the absence of such deals or unfavorable terms can have the opposite effect.

Funding and Cash Position: Atai's ability to secure funding through venture capital, public offerings, or other means influences its operational runway and growth prospects, impacting investor perception and stock price. A strong cash position provides stability and supports research and development.

News and Media Coverage: Positive news articles, scientific publications, or media attention surrounding Atai and the psychedelic medicine field can generate investor interest and drive up the stock price. Negative publicity can have the reverse effect.

Intellectual Property: The strength and breadth of Atai's intellectual property portfolio, including patents and trademarks, protects its competitive advantage and influences its long-term valuation. Strong IP provides more security for future earnings.

Management Team: The experience, expertise, and track record of Atai's management team inspire investor confidence. Changes or perceived weaknesses in leadership can impact stock performance.

People Also Watch

Research

Market Performance Overview: S&P 500 Rose 1.18%, Earnings Season Q1 2026, Crypto Positive Sentiment

Market Performance Overview: S&P 500 Rose 1.18%, Earnings Season Q1 2026, Crypto Positive Sentiment

Ghko B|--
Apple (AAPL) stock overview: Apple Q2 2026 earnings are coming, what to expect on April 30?

Apple (AAPL) stock overview: Apple Q2 2026 earnings are coming, what to expect on April 30?

Frances Wang|--
Crypto market outlook: South Africa Crypto Market Forecast to Reach $25 Billion by 2033

Crypto market outlook: South Africa Crypto Market Forecast to Reach $25 Billion by 2033

Ghko B|--
BTC, ETH, XRP: What’s going on with the top 3 cryptos?

BTC, ETH, XRP: What’s going on with the top 3 cryptos?

Ghko B|--
Best crypto brokers in South Africa (2026): Binance, Luno, Coinbase and more

Best crypto brokers in South Africa (2026): Binance, Luno, Coinbase and more

Ghko B|--

Latest news

Hormuz Strait Control: Iran's Post-War Maritime Ambitions and Global Repercussions

Emma Rose|--

Global Market Analysis and Geopolitical Shifts: An In-Depth Look

Emma Rose|--

Tesla Stock Plummets Over 5% on Disappointing Q1 Delivery and Production Figures

Sophia Claire|--

Latest Education Articles

Black Swan Events Explained: What They Mean for the Stock Market and Your Money

Black Swan Events Explained: What They Mean for the Stock Market and Your Money

Julian Parker|--
How to Use AI in Trading: Tools, Strategies, Benefits & Risks

How to Use AI in Trading: Tools, Strategies, Benefits & Risks

Julian Parker|--
How to Trade Bitcoin (BTC/USD) CFDs in South Africa: A Complete Beginner’s Guide for 2026

How to Trade Bitcoin (BTC/USD) CFDs in South Africa: A Complete Beginner’s Guide for 2026

Ghko B|--
Recommended Topics